Evaluation of Tolerability and Immunogenicity of GARDASIL in Healthy Females, Between 16 and 26 Years of Age, in India.
Phase of Trial: Phase III
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics; Registrational
- 13 Jan 2011 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 30 Sep 2010 Planned end date changed from 1 Apr 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 03 Feb 2010 New source identified and integrated (Clinical Trials Registry - India).